Related Experiment Video
Updated: Aug 20, 2025

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
Rutaecarpin reduces lipids by DGKθ-dependent activation of PPARα
Di Wu1, Jiheng Wang1, Yongxing Chang1
1Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, China.
Objective:
Lipid metabolic disorders pose a serious threat to human health, and currently no good treatments exist. In earlier studies by the authors, HepG2 cells with diacylglycerol kinase theta (DGKθ) knockout were found to cause significant lipid accumulation, suggesting that DGKθ may be a potential target for treating lipid metabolic disorders.
Methods:
A high-throughput screening of natural products targeting the potential signaling pathway of lipid metabolism was carried out in the DGKθ-T2A-luciferase knock-in HepG2 cell. RNA-sequencing and bioinformatic approaches were used to analyze the potential pathway by which rutaecarpin decreases lipids. Western blot and quantitative polymerase chain reaction were performed to investigate the mechanisms of rutaecarpin's reduction in lipid levels.
Results:
Rutaecarpin was found to significantly enhance DGKθ expression, and the potential mechanisms by which rutaecarpin accelerates lipid metabolism by targeting DGKθ was explored in vitro and in vivo. The results indicated that rutaecarpin could markedly reduce lipid accumulation in oleic acid-induced HepG2 cells and in high-fat diet-induced obese C57BL/6J mice by targeting the hepatocyte nuclear factor 1-beta (HNF1B)-DGKθ-peroxisome proliferator-activated receptor alpha (PPARα)-apolipoprotein C3 (APOC3) pathway.
Conclusion:
Rutaecarpin is effective in reducing lipid accumulation, and the development of a high-throughput screening platform based on a reporter knock-in cell line may facilitate the discovery of effective drugs for lipid metabolic disorders based on the DGKθ target.
Insights
Rutaecarpin effectively reduces lipid accumulation by targeting diacylglycerol kinase theta (DGKθ). This natural compound offers a promising therapeutic strategy for managing lipid metabolic disorders.
Area of Science:
- Biochemistry
- Pharmacology
- Metabolomics
Background:
- Lipid metabolic disorders represent a significant global health challenge with limited effective treatments.
- Previous research identified diacylglycerol kinase theta (DGKθ) knockout in HepG2 cells as a cause of substantial lipid accumulation, highlighting DGKθ as a potential therapeutic target.
- The development of novel therapeutic strategies for lipid disorders is urgently needed.
Purpose of the Study:
- To investigate the potential of natural products in targeting lipid metabolism pathways.
- To explore the mechanism of action of rutaecarpin in reducing lipid accumulation.
- To validate DGKθ as a therapeutic target for lipid metabolic disorders.
Main Methods:
- High-throughput screening of natural products using a DGKθ-T2A-luciferase knock-in HepG2 cell line.
- RNA-sequencing and bioinformatic analysis to elucidate the molecular pathways affected by rutaecarpin.
- In vitro and in vivo experiments, including Western blot and quantitative PCR, to confirm the effects of rutaecarpin on lipid metabolism in cell cultures and mouse models.
Main Results:
- Rutaecarpin significantly enhances diacylglycerol kinase theta (DGKθ) expression.
- Rutaecarpin demonstrably reduces lipid accumulation in oleic acid-induced HepG2 cells and high-fat diet-induced obese mice.
- The lipid-lowering effect of rutaecarpin is mediated through the hepatocyte nuclear factor 1-beta (HNF1B)-DGKθ-peroxisome proliferator-activated receptor alpha (PPARα)-apolipoprotein C3 (APOC3) signaling pathway.
Conclusions:
- Rutaecarpin is a potent natural compound effective in reducing lipid accumulation.
- Targeting DGKθ presents a viable therapeutic strategy for managing lipid metabolic disorders.
- A high-throughput screening platform utilizing reporter knock-in cell lines can accelerate the discovery of novel drugs for lipid metabolic disorders.
Related Concept Videos
GPCR Desensitization
GPCRs Regulate Adenylyl Cylase Activity
Cell Specific Gene Expression
cAMP-dependent Protein Kinase Pathways
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Cholesterol: Significance and Regulation
Considering cholesterol and...

